Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Viruses with RNA Genomes01:29

Viruses with RNA Genomes

35
RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
35
Viral Structure00:56

Viral Structure

62.4K
Viruses are extraordinarily diverse in shape and size, but they all have several structural features in common. All viruses have a core that contains a DNA- or RNA-based genome. The core is surrounded by a protective coat of proteins called the capsid. The capsid is composed of subunits called capsomeres. The capsid and genome-containing core are together known as the nucleocapsid.
62.4K
Subviral Agents01:29

Subviral Agents

20
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
20
Retroviruses02:33

Retroviruses

12.3K
Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
12.3K
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

46.1K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
46.1K
Introduction to Virus01:28

Introduction to Virus

62
Viruses are unique biological entities that blur the boundary between living and non-living systems. Although they lack cellular structure and metabolic processes, they can exhibit characteristics of life when infecting a host. Their defining feature is a nucleic acid core, composed of either DNA or RNA, encapsulated within a protein coat called a capsid. This simple structure allows them to invade host cells and use their machinery for replication efficiently.Viral Structure and...
62

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

c-FLIP as a master regulator of immune homeostasis and disease mechanisms.

Cell death & disease·2026
Same author

Host transcriptomic analysis reveals a defective intracellular environment that limits SARS-CoV-2 replication in CFTR-deficient airway epithelium.

Frontiers in cellular and infection microbiology·2026
Same author

When viruses meet cystic fibrosis: Insights into host-pathogen dynamics.

Microbiological research·2026
Same author

Beyond the Spike Glycoprotein: Mutational Signatures in SARS-CoV-2 Structural Proteins.

Infectious disease reports·2025
Same author

Chromosomal-level assembly of Magnusiomyces clavatus: novel genetic insights on an emerging fungal pathogen.

G3 (Bethesda, Md.)·2025
Same author

An Italian Single-Center Genomic Surveillance Study: Two-Year Analysis of SARS-CoV-2 Spike Protein Mutations.

International journal of molecular sciences·2025

Related Experiment Video

Updated: Jul 12, 2025

Assays for the Identification of Novel Antivirals against Bluetongue Virus
12:02

Assays for the Identification of Novel Antivirals against Bluetongue Virus

Published on: October 11, 2013

14.1K

Vector-Transmitted Flaviviruses: An Antiviral Molecules Overview.

Erica Diani1, Anna Lagni1, Virginia Lotti1

  • 1Department of Diagnostic and Public Health, Microbiology Section, University of Verona, 37134 Verona, Italy.

Microorganisms
|October 28, 2023
PubMed
Summary

Flaviviruses cause millions of infections yearly, with limited treatments available. This review explores promising antiviral compounds and challenges in developing effective flavivirus therapies.

Keywords:
DENVTBEVWNVYFVZIKVantiviraldrugflaviviruspublic healthzoonotic

More Related Videos

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

30.3K
High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
11:34

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

Published on: May 5, 2014

13.9K

Related Experiment Videos

Last Updated: Jul 12, 2025

Assays for the Identification of Novel Antivirals against Bluetongue Virus
12:02

Assays for the Identification of Novel Antivirals against Bluetongue Virus

Published on: October 11, 2013

14.1K
Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

30.3K
High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
11:34

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

Published on: May 5, 2014

13.9K

Area of Science:

  • Virology
  • Infectious Diseases
  • Drug Discovery

Background:

  • Flaviviruses cause significant global health issues, including Yellow Fever, dengue, West Nile, and Zika, leading to severe pathologies and an estimated 20,000 deaths annually.
  • Expanding geographical ranges due to climate and social factors increase flavivirus transmission.
  • Limited approved antiviral treatments exist for flavivirus infections, highlighting an urgent public health need.

Purpose of the Study:

  • To review current compounds under evaluation for treating flavivirus infections.
  • To outline the mechanisms of action for potential antiviral agents.
  • To discuss challenges encountered in clinical trials for flavivirus drug development.

Main Methods:

  • Literature review of ongoing studies and clinical trials for flavivirus antivirals.
  • Analysis of identified compounds targeting various steps of the viral life cycle.
  • Examination of challenges in flavivirus drug development and clinical evaluation.

Main Results:

  • Numerous compounds are being investigated in vitro and in vivo to inhibit flavivirus replication.
  • Several viral proteins exhibit high conservation, presenting viable targets for drug design.
  • The absence of approved antivirals remains a critical public health concern.

Conclusions:

  • Despite ongoing research, there is a significant lack of approved antiviral therapies for flaviviruses.
  • Identifying and developing effective treatments for flavivirus infections is crucial due to their widespread impact.
  • Further research and clinical trials are necessary to overcome challenges and bring new antivirals to patients.